In many cancers, overexpression/ activation of cMET occur, which may be responsible for tumorigenicity, metastasis, and immunosuppression.1,2 HGF/ cMET signaling is increased in breast cancer cells, especially in the Her2+ subtype. The gene discussed is MET; the disease is breast carcinoma.